Medifast, Inc. (MED) Balance Sheet

The shrinkage in total assets is largely driven by falling cash, which dropped from $115.3M in 2024Q3 to $58.4M in 2026Q3, and by a sharp reduction in net PP&E. This pattern suggests the company is consuming its balance sheet rather than reinvesting, and investors should monitor whether equity erosion continues at the current pace. The trend implies the business is becoming structurally smaller rather than temporarily cyclical.

The headline current ratio appears comfortable, yet the denominator reduction from total liabilities falling from $88.2M to $59.5M means the improvement warrants further investigation before being read as genuine strength. Cash declining roughly 49 percent from its 2024Q3 peak implies the cushion against operating losses is thinning. Liquidity may remain adequate near term, but the trajectory suggests the buffer is being drawn down.

Leverage is modest and does not appear to pose near-term refinancing pressure based on the reported figures. Debt has been fairly stable in the $12M to $28M range, suggesting it is not being used aggressively to fund losses. Because the company carries little debt, the principal balance sheet risk lies in equity erosion rather than creditor claims.

Equity has fallen from $210.1M to $180.3M over the period, and the retained earnings trend indicates accumulated losses are now consuming paid-in capital. This does not by itself prove the company's future viability, but it suggests the equity base is shrinking in step with weakening profitability. Investors should monitor whether further losses force additional restructuring or capital actions.